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the CC BY-NC-ND license (http://creaAbstract Prostate cancer is an androgen-dependent cancer with unique metabolic features
compared to many other solid tumors, and typically does not exhibit the “Warburg effect”.
During malignant transformation, an early metabolic switch diverts the dependence of normal
prostate cells on aerobic glycolysis for the synthesis of and secretion of citrate towards a more
energetically favorable metabolic phenotype, whereby citrate is actively oxidised for energy
and biosynthetic processes (i.e. de novo lipogenesis). It is now clear that lipid metabolism is
one of the key androgen-regulated processes in prostate cells and alterations in lipid meta-
bolism are a hallmark of prostate cancer, whereby increased de novo lipogenesis accompanied
by overexpression of lipid metabolic genes are characteristic of primary and advanced disease.
Despite recent advances in our understanding of altered lipid metabolism in prostate tumori-
genesis and cancer progression, the intermediary metabolism of the normal prostate and its
relationship to androgen signaling remains poorly understood. In this review, we discuss the
fundamental metabolic relationships that are distinctive in normal versus malignant prostate
tissues, and the role of androgens in the regulation of lipid metabolism at different stages
of prostate tumorigenesis.
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The prostate gland is exquisitely sensitive to androgenic
hormones, and this dependence has been exploited to treat
metastatic prostate cancer (PCa) since the 1930s. Whereas
the interplay between androgen action and the unique lipid
metabolic phenotype of PCa cells has been extensively
studied [1e8], our knowledge of normal metabolism in the
prostate lags considerably behind that of other tissues such
as liver or heart. Understanding lipid metabolism in the
normal prostate is essential to reveal the intermediary
processes that mediate cell transformation, and in turn
provide new insights into PCa detection, preventive and/or
therapeutic strategies that are not evident from current
experimental cancer models. This review article aims to
provide a contemporary perspective on androgens and their
impact on different aspects of lipid metabolism in normal
and malignant prostate tissues, and highlight some recently
identified metabolic vulnerabilities related to androgen
action.
2. Normal prostate metabolism and androgens
The main function of the prostate is to produce and secrete
prostatic fluid, which constitutes approximately one-third
of the total volume of semen. Prostatic fluid is comprised of
enzymes including prostate-specific antigen (PSA) that are
responsible for liquefying semen, zinc, lipids and citrate.
High citrate production and secretion are unique charac-
teristics of the prostate; citrate concentration in prostate
cells is about 1.0e3.0 mmol/L compared with only 0.1e0.5
mmol/L in other mammalian cells. Accordingly, citrate
concentration in the prostatic fluid is about 24e130 mmol/
L, which is 240e1 300-fold greater than that in blood
plasma [9e11]. Typically, citrate is either retained and
oxidized in the mitochondria to generate energy as an
essential intermediate in the citric acid cycle, or is expor-
ted into the cytoplasm where it is cleaved by citrate lyase
(ACLY) to generate acetyl-CoA, which is used for fatty acid
synthesis. The complete oxidation of citrate via the citric
acid cycle fuels the cell with 12 mol ATP/mol citrate and
24 mol ATP/mol glucose oxidized. However, as described
above, the prostate secretes enormous quantities of cit-
rate, depriving prostate cells of a major pool of energy.
Although the function of citrate within the prostatic fluid is
not fully understood, it presumably contributes to the
seminal fluid buffering capacity, chelation of calcium, zinc
and other cations, and as an energy source to maintain
sperm viability and/or for capacitation processes [12e18].
Studies onhumanand rat ventral prostate tissues or isolated
prostate epithelial cells have revealed the dependence of
prostate cells on aerobic glycolysis [19e24]. The aerobic
glycolysis metabolic phenotype in normal prostate tissues is
accompanied by another phenotype of secretion of high citrate
concentrations within the prostatic fluid. However, PCa cells
exhibit a decrease in citrate concentration, which suggests a
metabolic transformation from citrate producing cells into
citrate oxidizing cells [11]. In support of this, it was recently
reportedthat significantly lower levelsofcitrateweredetected
in PCa tissues compared with normal prostate tissues as
evaluated using desorption electrospray ionization massspectrometry (DESI-MSI) [25]. This switch in citrate fate is
suggested to take place by inhibition of the m-aconitase
enzyme by zinc (Fig. 1). M-aconitase is responsible for the
stereo-specific isomerization of citrate to isocitrate. The cit-
rate/isocitrate ratio in most mammalian tissues is 10:1
comparedwith30:1 inprostatecells, suggestingan inhibitionof
this key enzymatic activity [26]. In addition to producing and
secreting large concentrations of citrate, normal prostate tis-
sues are further characterized by the ability to uptake and
accumulate large concentrations of zinc [27e29]. Zinc con-
centration is 10-fold greater in normal prostate tissues
compared with other soft tissues, and its concentration in the
prostaticfluid is500-foldgreater than inbloodplasma[30].Zinc
inhibits m-aconitase activity, paving the way for prostate cells
to halt citrate oxidation [31,32]. In addition to the secretion of
citrate, the prostate is also a source of cholesterol, which
comprises a major proportion of the seminal fluid [33].
Few studies have focused on the impact of androgen re-
ceptor (AR) signaling in normal prostate cell metabolism
[34e36], and have largely focused on the role of androgens in
increasing the intracellular citrate pool and lipid biosynthesis.
The former is accomplished by increasing citrate production
via enhanced availability of citrate precursors, acetyl-CoA
and oxaloacetic acid, and/or decreased citrate consump-
tion. Androgens were found to induce pyruvate oxidation by
increasing the expression of pyruvate dehydrogenase E1
component subunit alpha (PDHE1a) [37], resulting in an in-
crease in acetyl-CoA. Androgens were also reported to induce
aspartate uptake and transamination processes by inducing
expression of the aspartate transporter (EAAC1) and aspar-
tate aminotransferase (mAAT ) genes [38e41], providing cells
with oxaloacetic acid. Moreover, androgens can induce zinc
uptake by the prostate [42,43], inhibiting citrate oxidation
(Fig. 1). 5a-dihydrotestosterone (DHT) increased mAAT
expression in PC3 cells expressing AR [44], and in isolated pig
prostate epithelial cells [45]. Testosterone increases the
levels of m-aconitase mRNA and the transcription rates of m-
aconitase in rat ventral prostate cells, pig prostate cells, and
human malignant prostate cells (LNCaP and AR-PC-3) [36].
Testosterone up-regulated EAAC1 expression in rat ventral
prostate epithelial cells [46]. PDHE1a expression was stimu-
lated in response to testosterone in ventral prostate epithelial
cells, rat ventral prostate cells, and in PC3 cells transfected
with AR [37,47]. In contrast with this induction of citrate
accumulation, androgens were found to induce m-aconitase
activities in normal and malignant prostate cells [34e36,48].
Using castrated mature monkey models, androgens were
found to control enzymes involved in the citric acid cycle,
such as isocitrate dehydrogenase (IDH) and malate dehydro-
genase (MDH) [49]. It is plausible that this induction is not
enough to counteract other processes that increase citrate
levels in prostate cells. Of note, the effects of testosterone in
rodents were lobe-specific; testosterone induced m-aconitase
mRNA expression in rat ventral prostate lobes but not in the
dorsal lobes and decreased m-aconitase mRNA expression in
the lateral lobes [50]. There is no consensus as to which of
these rodent lobes is the most similar to the human prostate
peripheral zone, where most prostate tumours arise [24,51]
and although there are some anatomical resemblances be-
tween the rodent dorsolateral lobe and the human peripheral
zone, molecular comparison studies are warranted. In
contrast to humans, rodents rarely develop spontaneous PCa
Figure 1 Metabolic landscape of prostate cancer progression (from normal prostate to malignant to metastatic/CRPC). Normal
prostate epithelial cells exhibit high rates of aerobic glycolysis and low rates of oxidative phosphorylation. Glucose is used for citrate
production and secretion, resulting in an impaired TCA cycle; this process is facilitated by zinc and aspartate through inhibition of m-
aconitase and supply of metabolic precursors (i.e. oxaloacetate). Alternatively, citrate may be used for lipid biosynthesis through
androgen-mediated activation of lipogenic enzymes. During malignant transformation, prostate cancer cells exhibit increased
oxidative phosphorylation and hence, reactivate the TCA cycle to oxidize citrate for energy production. Instead of glucose, FFAs are
the dominant bioenergetic substrates that feed into the TCA cycle for energy production. More importantly, de novo lipogenesis is
enhanced at this stage of disease through the up-regulation of AR-regulated lipogenic enzymes. Despite initial positive responses to
androgen-deprivation therapy, patients eventually progress to CRPC. AR signalling is maintained in CRPC; AR resistant mechanisms
such as the AR-variants (AR-Vs) and/or indirect activation of alternative metabolic pathways (i.e. SREBP) play a role in driving the
androgen-mediated lipogenic phenotype that may contribute to prostate cancer progression and treatment resistance. Notably,
increased aerobic glycolysis or the Warburg effect is observed in advanced stages of the disease/CRPC. Words highlighted in red: AR-
regulated genes. Thin/dotted lines: Baseline level; thick lines: Up-regulated. TCA, tricarboxylic acid cycle; PDH, pyruvate dehy-
drogenase; MAAT, aspartate aminotransferase; FASN, fatty acid biosynthesis; ACC, acetyl-CoA-carboxylase; SCD, stearoyl-CoA-
desaturase; OXPHOS, oxidative phosphorylation; CRPC, castrate-resistant prostate cancer; AR, androgen receptor; FFAs, lipids or
free fatty acids; MDH, malate dehydrogenase; a-KG, alpha ketoglutarate; AR-Vs, androgen receptor variants; CPT1, carnitine pal-
mitoyltransferase 1; FAS, fatty acid synthesis. Created with BioRender.com.
260 C.Y. Mah et al.[41], suggesting that rodent models should be supplemented
with better human-mimic models.
Other studies on androgens and normal prostate tissue
metabolism have focused on lipogenesis. Androgens were
found to be essential in the prostate for lipid biosynthesis.
Castration of the rat or monkey results in repression of
lipogenic enzymes including ATP citrate lyase (ACLY),
fatty acid synthase (FASN) and acetyl-CoA-carboxylase
(ACC), and decreased total prostatic lipid content.
Conversely, androgen administration after castration
restored these lipogenic enzyme activities and lipid levels
to baseline [49,52e55].
The metabolism of other nutrients such as fatty acids or
amino acids in normal prostate tissues have not beenexamined thoroughly yet. It is surprising that our
understanding of androgen regulation on prostate tissues is
limited to relatively few processes and genes, given that
androgens are the main orchestrator of prostate functions
and physiology. Whereas prostate epithelial androgen re-
ceptor knockout (PEARKO) mouse models exist, to date
there has been no investigation on the role of AR on pros-
tate cell metabolism using these models. Similarly, little is
known about the altered metabolic pathways in prostate
cells during oncogenic transformation, and whether these
alterations are driving malignancy or reflect changes to
other genes or signaling pathways. One obvious manifes-
tation of PCa is a striking decrease in citrate secretion into
the prostatic fluid [11]. Redirecting citrate into the
Fatty acid metabolism in the prostate 261mitochondria allows cell to use other nutrients to generate
energy, including fatty acids. Fatty acid and lipid
metabolism, with a focus on the androgen-regulated fac-
ets, will be discussed in the following sections.
3. Androgens and lipid metabolism in PCa
In the 1920s, Warburg [56,57] observed that rapidly prolif-
erating tumor cells consume glucose at significantly higher
rates compared to normal cells. Interestingly, most of the
glucose-derived carbon was secreted as lactate rather than
undergoing complete oxidation. This phenomenon is known
as the “Warburg effect”. This provides proliferating cancer
cells several advantages including (1) rapid and abundant
ATP/energy production and (2) essential intermediates/
precursors needed for biosynthetic pathways [58,59]. More
importantly, the Warburg effect has become the basis for
the development of 18F-fluorodeoxyglucose positron emis-
sion tomography (FDG-PET) as a staging tool for diverse
types of cancers.
The Warburg effect is a classic example of metabolic
reprogramming in cancer. However, unlike most solid tu-
mors, PCa typically does not exhibit the “glycolytic switch”
(or Warburg effect) and is poorly detected with FDG-PET due
to its weak avidity for glucose [60]. Given that rapid cell
proliferation in malignant tumors requires increased energy
supply, alternative sources of energy likely fuel PCa growth.
Early studies revealed that primary PCa is associated with
alterations in lipid metabolism (see below). Banerjee et al.
[25] observed an increase in the glucose to citrate ratio in
PCa tissues compared with benign prostate tissues using
DESI-MSI. This difference was largely driven by the marked
decrease in citrate levels in PCa while the increase in
glucose signal intensity was less pronounced. The authors
subsequently detected higher levels of lipids in PCa
compared with normal prostate tissues and proposed the
shunting of citrate into lipogenesis and oxidation in PCa [25].
Conversely, an increased aerobic glycolysis phenotype has
been reported in advanced stages of PCa, while other
studies have reported a spectrum in the degree of glycolysis
between androgen-dependent and androgen-independent
PCa [61,62]. Moreover, increased glucose utilization as
indicated by higher FDG-PET avidity in PCa patients was able
to predict biochemical recurrence and PCa progression to
castrate-resistant PCa (CRPC) [63]. More recently, it was
found that AR-dependent CRPC exhibited higher aerobic
glycolysis in vivo using patient-derived xenograft models
[64]. In addition, Bok et al. [65] demonstrated using trans-
genic mouse prostate models that an increased Warburg
effect was essential to support tumour progression and
metastasis, particularly in hypoxic conditions. Taken
together, these findings suggest that the Warburg effect is
still applicable in PCa and the binary notion that PCa is non-
glycolytic should be reconsidered.
3.1. Role of the AR in lipid metabolism
The AR modulates multiple metabolic gene networks in PCa.
In support of this, combined analysis of direct AR binding
targets and androgen regulated genes revealed a significant
enrichment of metabolic targets in LNCaP and VCaP PCacells [66]. Interestingly, lipid metabolism has been identified
as one of the key cellular processes affected by androgens.
We previously reported that exposure of LNCaP cells to an-
drogens induced a marked accumulation of lipids such as
cholesteryl esters and triacylglycerols. Further analysis of the
origins of the accumulated lipids revealed that the observed
lipid accumulation was due to androgen stimulated de novo
lipogenesis, rather than uptake from extracellular sources
[67]. More importantly, this lipid accumulation was abrogated
by treatment with an AR-antagonist and was not observed in
AR-negative PC3 and DU-145 PCa cells. Subsequently,
numerous studies have reported androgen stimulation of the
expression of diverse lipogenic enzymes, including several
additional enzymes involved in lipid binding, uptake, meta-
bolism and transport [2,3] (Fig. 2). Androgenic regulation of
these genes has also been validated in several cell line RNA
microarray and sequencing studies [66,68,69]. Overall, these
findings highlighted an anabolic program downstream of the
AR signaling axis to facilitate PCa development and
progression.3.2. Androgens and lipid biosynthesis
Increased de novo lipogenesis is an early hallmark of PCa
tumorigenesis and is significantly associated with PCa pro-
gression and poor disease survival outcomes [70e73]. More
than half a century ago, it was demonstrated that cancer
cells shunted glucose-derived carbons from the mitochon-
drial Kreb’s cycle to the cytosol for fatty acid synthesis
(FAS) despite an abundant supply of extracellular lipids
[74]. In rapidly proliferating cells, citrate generated from
glucose and glutamine metabolism is essential for the
production of acetyl-CoA which is the building block for de
novo lipogenesis. In line with this observation, candidate-
gene expression studies have reported tumor-related
overexpression of key enzymes involved in lipogenesis
that are essential for development and progression of PCa
[75]. Notably, androgens have been reported to regulate
the expression of lipogenic and lipid-modifying enzymes
[76,77], such as FASN, ACC and steroyl-CoA-desaturase
(SCD), to meet the growing demands of PCa cells for
lipids, which serve as building blocks for membrane pro-
duction, energy supply and storage, and act as mediators of
intracellular signaling [78]. FASN forms a fatty acid by
catalysing successive condensation reactions from malonyl-
CoA and acetyl-CoA substrates. Overexpression of FASN
occurs at the early stages of PCa pathogenesis and has been
correlated to poor prognosis and reduced disease-free
survival [71,79]. Moreover, elevated expression of FASN
has been associated with aggressive PCa and metastasis to
the bone [70]. ACC catalyses the rate-limiting step in FAS by
converting acetyl-CoA to malonyl-CoA. Two isoforms, ACC1
and ACC2 exist: (1) ACC1 primarily produces malonyl-CoA to
serve as a substrate for FAS; (2) ACC2 produces malonyl-CoA
primarily to inhibit fatty acid b-oxidation via allosteric in-
hibition of carnitine palmitoyltransferase 1 (CPT1) [80]. It
has been demonstrated that depletion of ACC1 expression
by siRNA inhibited cell proliferation and induced caspase-
mediated apoptosis in PCa cells, but non-malignant cells
were unaffected [81]. Similar results were observed
through chemical inhibition of ACC1 and ACC2 by Soraphen
Figure 2 Overview of lipid metabolism in prostate cancer. Androgens regulate a number of lipid metabolic pathways in prostate
cancer cells, including lipid uptake, biosynthesis and degradation. The AR directly (via binding of AR to the ARE) or indirectly (via
activation of SREBP) regulates key lipid metabolic genes. Lipids can be derived from lipolysis of adipocytes or from circulating
lipoproteins (LDL, HDL, VLDL). Alternatively, lipids can be synthesized endogenously by the cells via enzymes ACC and FASN.
Androgens up-regulate lipid transporters that transport lipids or free fatty acids to the mitochondria for fatty acid oxidation (b-
oxidation) or de novo lipogenesis. Free fatty acids are shuttled into the mitochondria as Acyl-CoAs by coupling with CPT1 (a
mitochondrial transporter); a cyclical series of reactions result in the shortening of Acyl-CoA and the production of energy in the
form of ATP via the TCA cycle. Citrate produced from the TCA cycle may also be cleaved to produce Acetyl-CoA, which is a
precursor for de novo lipogenesis in the cytosol. Synthesized fatty acids may be further modified (i.e. degree of saturation via SCD)
to generate a variety of lipids such as phospholipids that compose the plasma membranes, to promote lipid droplet production or to
act as oncogenic signalling molecules to drive disease progression. Words in red Z androgen-regulated genes. ARE, androgen
response element; SRE, SREBP response element; AR, androgen receptor; LDL, low density lipoprotein; HDL, high density lipo-
protein; VLDL, very low density lipoprotein; FASN, fatty acid biosynthesis; TCA, tricarboxylic acid cycle; SCD, stearoyl-CoA-
desaturase; SREBP, sterol response element binding protein. Created with BioRender.com.
262 C.Y. Mah et al.A in both androgen-dependent and androgen-independent
PCa cells [82]. Generally, fatty acids are composed of a
terminal carboxyl group and an alkyl chain which can un-
dergo further modifications performed by desaturases or
elongases. The rate-limiting enzyme SCD1 catalyses the
biosynthesis of monounsaturated fatty acids (MUFA) from
saturated fatty acids (SFA) by introducing a cis-double bond
to the acyl chain, specifically palmitate and stearate to
yield palmitoleate and oleate. It has been reported that
PCa cells upregulate lipid biosynthesis to generate SFA and
MUFA-rich phospholipids that partition into detergent-
resistant lipid rafts to markedly alter signal transduction
cascades, vesicular trafficking and cell migration [83,84].
Alterations in the desaturation index (MUFA to SFA ratio)
affect phospholipid composition and hence, cancer cell
behaviour [85]. One of the potential consequences of
this altered desaturation ratio is changes to membrane
fluidity [86]. Of note, Fritz et al. [87] reported an increase
in MUFA/SFA ratio in human PCa patient tissues compared
with normal prostate tissues. Consistent with thisobservation, the authors found enhanced expression of
SCD1 in androgen-sensitive and resistant PCa cell lines and
patient tissues. More importantly, SCD1 inhibition was
shown to repress proliferation of androgen-dependent
LNCaP and androgen-independent C4-2 PCa cells in vitro
and in prostate tumor xenografts [87]. This was attributed
to the inhibition of the AKT signaling pathway due to a
decrease in the generation of phosphatidylinositols (pre-
cursors of a known AKT activator) following pharmacolog-
ical inhibition of SCD1 (BZ36).3.3. Androgens and fatty acid oxidation (FAO)
FAO is the dominant bioenergetic pathway in PCa [88,89].
The early “metabolic switch” towards citrate oxidation
during PCa development coupled with the low glucose
avidity of PCa (see above) diverts the focus away from
glucose catabolism as the major source of energy/ATP to
fatty acids. Mounting evidence suggests that FAO plays a
Fatty acid metabolism in the prostate 263crucial role in (1) sensitizing cancer cells to apoptosis in-
duction by pro-apoptotic agents [90], (2) impairing NADPH
production resulting in oxidative stress-induced cell death
[91], and (3) increasing resistance to radiation and
chemotherapeutic agents [92]. Moreover, it was proposed
that FAO could play a role in driving specific oncogenic
pathways (i.e. Src signaling) associated with tumor pro-
gression and metastasis [93]. Altogether, these findings
suggest that cancer cells depend on FAO for their survival
and disease progression, particularly in cancers such as PCa
which rely on FAO as a key energy source. In line with this
observation, a recent study showed that knockdown of a
FAO enzyme, enoyl-CoA-isomerase 2 (ECI2) inhibited PCa
cell proliferation and activated cell death in LNCaP and
VCaP PCa cells [4]. This study demonstrated that using
ChIP-qPCR androgen stimulation resulted in a 6-fold in-
crease in AR binding to the putative AR binding site of ECI2
and enhanced ECI2 mRNA expression [4]. While androgenic
regulation of de novo lipogenesis has gained considerable
attention, this suggests that androgens may also stimulate
FAO for growth and survival. A previous study found that
androgens promoted the complete oxidation of fatty acids
in LNCaP and VCaP PCa cells, and inhibition of FAO via
treatment with Etomoxir (inhibitor of CPT1) suppressed
androgen-mediated PCa cell growth [94]. Overexpression of
CPT1 (the rate-limiting enzyme of mitochondrial FAO) has
been reported in several cancers, including PCa [88,95,96],
and Etomoxir causes toxic lipid accumulation and, subse-
quently, the development of endoplasmic reticulum stress
leading to PCa cell apoptosis [96]. Interestingly, this study
also showed a reduction in expression AR-regulated genes
(PSA, NKX3.1) following a significant decrease in AR as a
result of FAO inhibition, suggesting a feed-forward loop to
sustain PCa cell growth [96]. Overall, FAO is an important
component of cancer metabolism that remains underex-
plored in PCa, and further study of this process may also
inform new mechanisms of clinical resistance to androgen
targeting therapies.3.4. Androgens and lipid uptake
In light of enhanced de novo lipogenesis as a hallmark of
PCa, and the fact that fatty acids are the dominant meta-
bolic substrate for the development and progression of PCa,
it was recently reported that exogenous lipids are the
major contributor to lipid biosynthesis and oxidation in PCa
[97]. Exogenous lipids can be derived from adipose tissue
lipolysis or the breakdown of triglycerides contained in
circulating lipoproteins. Moreover, the prostate is sur-
rounded by peri-prostatic adipose tissue which has the ca-
pacity to directly supply substantial quantities of fatty
acids [98,99]. In line with this, recent studies have
demonstrated that increased lipid uptake in PCa cells can
drive proliferation and potentially invasiveness [98,100].
Furthermore, PCa cells co-cultured with peri-prostatic
derived adipocytes from obese mice showed enhanced
migratory properties compared with lean mice [101].
Mechanistically, androgens have previously been reported
as stimulating lipid uptake in androgen-responsive PCa cells
through increased expression of FABPpm (a transporter
protein) [102]. More recently, it was reported thatandrogens significantly increased cellular lipid uptake
(including fatty acids, cholesterol and lipoproteins) in AR-
positive PCa cells (LNCaP, VCaP, C4-2B and DuCaP) via
direct AR-mediated induction of several lipid transporters
[100]. This effect was abrogated when cells were co-
treated with the AR antagonist enzalutamide. Notably, it
was demonstrated that androgen-enhanced lipid uptake
was maintained in LNCaP PCa cells under cell cycle arrest.
This suggests that AR regulated lipid uptake is independent
of cell cycle progression and proliferation, and is not indi-
rectly caused by lipid biomass demand as a requirement for
cell division [100]. Moreover, this study also confirmed the
association of these lipid transporters with PCa progression
from localized disease to bone metastatic disease [100]. In
view of the critical roles for fatty acid uptake in PCa, CD36,
a major transporter for exogenous fatty acids into cells, has
been reported to play critical roles in cancer progression,
metastasis and epithelial-to-mesenchymal transition in
several tumour types [103e105]. In the context of PCa, it
was shown that DHT significantly increased CD36 expres-
sion, and this effect was abrogated by enzalutamide
treatment [100]. In addition, it was shown that CD36 was
expressed at a higher level in metastatic disease (although
there was no evidence for increased CD36 protein expres-
sion in tumor regions of human PCa tissues relative to
benign regions, stromal and epithelial cells) and that high
expression of CD36 was associated with reduced relapse-
free survival in PCa [98]. It was demonstrated that CD36
blockade reduces fatty acid uptake, resulting in a reduction
of cancer-mediated lipid biosynthesis from fatty acid pre-
cursors and accumulation of oncogenic lipid signaling mol-
ecules, ultimately attenuating PCa growth and progression
in cultured cells (LNCaP and PC3) and patient-derived
xenograft (PDX)-derived organoids [98]. Given that anti-
tumor effects of inhibiting lipogenesis can be rescued by
the addition of exogenous fatty acids, lipid uptake poses an
important mechanism of treatment resistance to inhibitors
of de novo lipogenesis. Accordingly, this study demon-
strated in PDX-derived human organoids that CD36
blockade enhanced the efficacy of de novo lipogenesis in-
hibition [98].3.5. Cross-talk between lipid metabolic processes
in PCa
Taken together, the above findings suggest that androgens
actively regulate different aspects of lipid metabo-
lismdbiosynthesis, degradation and uptakedthat are
essential for driving PCa tumorigenesis and disease pro-
gression. Intriguingly, androgens stimulate both FAO and
FAS in PCa cells suggesting that an intricate balance may
exist between these processes to provide both biomass
generation and energy required to support PCa cell growth
and survival [78]. It was previously considered that simul-
taneous mitochondrial FAO and cytosolic FAS are incom-
patible due to the inhibition of CPT1 by malonyl-CoA.
However, studies have shown that genetic manipulation of
ACC1 or ACC2 in cancer cells may exert different outcomes
in terms of FAO and FAS [106]. ACC2-generated malonyl-
CoA can inhibit CPT1, blocking fatty acid transport to the
mitochondria and its subsequent b-oxidation, while
264 C.Y. Mah et al.malonyl-CoA generated by ACC1 serves as an intermediate
for FAS and exert no suppressive effects on CPT1 [107,108].
In addition, FAO can contribute to the accumulation of
acetyl-CoA in the cytoplasm that is needed to initiate FAS,
thereby supporting each other. On the basis of this idea,
not only do the levels of acetyl-CoA and malonyl-CoA
determine which metabolic pathways are activated, but
also the ACC1 and ACC2 localization-dependent compart-
mentalization of these metabolites that allow FAO and FAS
to occur simultaneously and independently from each other
[95,107,109]. Alternatively, FAO may also play a protective
role during conditions of metabolic stress such as hypoxia or
glucose deprivation. Schlaepfer et al. [110] reported that
LNCaP, C4-2B and DU-145 PCa cells were significantly
enriched in triglycerides due to induction of lipogenic genes
in response to hypoxic stress, and proposed that the accu-
mulated lipids could support growth following reoxygena-
tion. Accordingly, the inhibition of lipid utilization via
treatment with etomoxir and shRNA-mediated CPT1
knockdown significantly compromised hypoxic PCa cell
proliferation following reoxygenation. Altogether, these
findings imply the importance of both FAO and FAS to pro-
mote tumour survival. In line with this observation, it has
been shown that simultaneously targeting FAS and FAO
significantly decreased PCa cell viability and AR expression
[96]. Further research is needed to elucidate the precise
mechanism of AR-mediated metabolic switching between
de novo lipogenesis and FAO.
One possible explanation could be the cross-talk be-
tween AR and other metabolic or oncogenic pathways. A
recent study reported that androgens induce mTOR reloc-
alization to the nucleus to drive androgen-mediated
metabolic reprogramming of PCa cells [111]. It was subse-
quently demonstrated that SREBF1, which acts as a down-
stream effector of the AR/mTOR signalling axis, helps
regulate the balance between citrate consumption for
mitochondrial energy production and as a carbon source for
FAS in the cytoplasm [112]. These findings suggest that AR
coordinates its actions with other transcription factors or
oncogenes to establish or fine tune specific metabolic
programs in PCa cells. Correspondingly, other transcrip-
tional co-activators and signalling pathways that interplay
with the AR signalling axis such as PGC-1a and estrogen
related receptor gamma (ERRy) have also been described
[94,113]. However, it remains to be determined how these
metabolic pathways can be most optimally targeted in a
setting of PCa.3.6. Direct versus indirect regulation of lipid
metabolic genes by AR
A major transcriptional regulator of lipogenic enzymes is
the sterol response element binding protein 1 (SREBP1)
transcription factor. Previous studies have shown that
SREBP1 is androgen-regulated and that androgens activate
SREBP1 expression via elevated expressions of the SREBP1
cleavage activating protein (SCAP) [3,114]. In line with this
observation, androgen-induced lipogenic genes such as
FASN harbor SREBP1-binding sites. Furthermore, SREBP1
induces fatty acid and lipid droplet formation and accu-
mulation in AR-positive PCa cells. In contrast, severalstudies have shown that inhibition of SREBP1, achieved by
shRNA knockdown or synthetic inhibitors (i.e. fatostatin)
repressed expression of key lipogenic enzymes and sup-
pressed growth of tumor xenografts [75,115,116]. Intrigu-
ingly, it was also shown that the expression of AR was, in
turn, regulated by SREBP1 via binding of SREBP1 upstream
of the AR gene [117]. This creates a positive feedback loop
for the expression of lipogenic enzymes as well as AR
expression and function. Collectively, these findings sug-
gest that androgens can exert a coordinate control over
lipogenesis that is regulated by the reciprocal relationship
between AR and SREBP1 in support of PCa growth and sur-
vival (Fig. 2). While the androgenic regulation of SREBP1
has largely been reported in the context of PCa, little is
known about the relationship between the AR and SREBP1
signaling, and the various roles of SREBP1 signaling in
normal prostate cells. Elevated SREBP1 protein levels were
reported in clinical human prostate tumours compared with
normal prostate tissue or benign prostatic hypertrophy
tissue [118]. Previous studies have shown that castration
decreases expression of lipogenic enzymes in rat ventral
prostate tissues, and that the effects were restored upon
androgen treatment [52]. Given that these enzymes (i.e.
FASN, ACLY, ACC) are known to be regulated by SREBP and
that they harbour SREBP-binding sites, it is plausible that
SREBPs may be involved in the coordinated activation of
lipogenic gene expression by androgens in the normal
prostate. Intriguingly, this study also demonstrated that
androgen deprivation resulted in a marked decrease of
mature nuclear-SREBP1 (nSREBP1) in the normal prostate
in vivo; in contrast, readministration of testosterone
completely restored nSREBP1 protein levels [52]. Never-
theless, the precise mechanism underlying the coordinated
activation of the lipogenic phenotype by androgens and
SREBP1 in the context of normal prostate cells remains to
be elucidated.
Genome-wide analyses of AR binding and activity also
suggest a distinct role for the AR in direct transcriptional
regulation of lipogenic genes. Based on their proximity to
AR binding sites [66,119] and their transcriptional regula-
tion by androgens, genes involved in lipid metabolism and
other key cellular metabolic processes have the potential
to be directly regulated by the AR in malignant and non-
malignant PCa cells [3]. This suggests that in addition to
the effects of androgens on transcriptional activators such
as SREBP1, androgens may also directly stimulate a coor-
dinated metabolic network to regulate energy production
and biosynthesis in PCa.
4. Effects of ADT on lipid metabolism
4.1. Metabolic effects of ADT
The current standard treatment for advanced and meta-
static PCa is ADT [120]. This targets androgen signaling in
PCa by reducing circulating levels of androgen or by
blocking binding of androgens to the AR. Despite initial
positive responses to ADT, the majority of patients even-
tually proceed to become resistant to ADT while main-
taining functional AR signaling. This stage of cancer
is termed CRPC. Several mechanisms of resistance to
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expression, AR point mutations and constitutively active AR
splice variants) and AR-independent mechanisms (i.e.
glucocorticoid receptor [GR] activity) have been described.
Accordingly, multiple clinical attempts to further suppress
AR activity have been made. In spite of recent approval of
novel AR-targeted therapies (e.g. enzalutamide), meta-
static CRPC (mCRPC) remains incurable, with patients
having a median survival of less than 2 years.
While there is abundant evidence that ADT has profound
effects on systemic metabolism, few studies have exam-
ined the effects of ADT on lipid metabolism in PCa cells. An
earlier study by Ettinger et al. [118] observed that
androgen-regulated genes (i.e. PSA) including SREBP1 were
significantly decreased following androgen deprivation in
prostate tumours. Given that SREBP1 is a known transcrip-
tional activator of genes involved in lipogenesis and
cholesterol synthesis, androgen withdrawal resulted in a
decrease in several genes involved in fatty acid biosynthesis
(FASN), energy production (ACBP) and cholesterol synthesis
(FDPS). Intriguingly, another study linked Siah2 (an E3
ubiquitin ligase) to regulation of AR target genes associated
with sterol and lipid metabolism [121]. This was attributed
to the finding that SREBF1 was a Siah2-dependent
androgen-responsive gene, consistent with their down-
regulation in Siah2 knockdown PCa cells. Of note, Siah2
expression was significantly reduced after ADT and is
required for PCa cell growth under androgen-deprivation
conditions in vitro and in vivo, suggesting that Siah2-
regulated lipid metabolism may contribute to CRPC [121].
More recently, Alsannawi et al. [122] investigated the role
of SLCO-encoded transporters (proteins that transport bile
acids, xenobiotics, steroid conjugates and drugs) in
response of primary PCa to ADT. Despite the small sample
sizes, the authors observed clear differences in SLCO
expression levels suggesting that ADT-induced changes in
PCa SLCO transporters may influence steroid uptake and
response to ADT, including uptake and response to PCa
therapies (i.e. abiraterone). Altogether, these studies have
begun to shed light into the connection between ADT and
lipid metabolism in PCa cells, but much more work is
needed to distinguish between the systemic effects of ADT
on patient metabolism that may also impact on PCa cell
properties.4.2. Resistance to ADT: The role of lipid metabolism
Overexpression of key lipid biosynthetic enzymes in PCa is
characteristic of both primary and advanced disease [123].
In view of the relationship between androgens and lipid
metabolism, several studies have reported that genes
mediating the lipogenesis pathway (i.e. FASN, SREBP1) that
were initially suppressed following castration were subse-
quently up-regulated or re-activated during the emergence
of CRPC [70,118,124]. Indeed, AR-mediated lipogenesis is a
highly-conserved metabolic feature of CRPC (Fig. 1), sug-
gesting the potential of lipid metabolism as a key survival
pathway that promotes resistance [124].
As AR signaling is initially repressed during ADT, it is
plausible that other genes or pathways critical to survival
(including metabolic adaptations) are activated to helpfacilitate progression to CRPC. This includes, but is not
limited to, lipid metabolism; FAS and cholesterol synthesis
provide CRPC cells with fatty acids for energy and mem-
brane synthesis, and cholesterol allows intratumoral de
novo synthesis of androgens. Previous studies have reported
overexpression of a key enzyme in cholesterol synthesis,
3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) in
enzalutamide-resistant PCa cells [125]. Notably, a combi-
nation of simvastin and enzalutamide significantly inhibited
the growth of enzalutamide-resistant PCa cells in vitro and
in vivo [125]. Another study demonstrated that silencing
the expression of ELOVL7 (a fatty acid elongase enzyme)
reduced growth of CRPC xenograft tumours in mice [124].
Furthermore, Flaig et al. [126] showed that targeting FAO
via inhibition of CPT1A enhanced sensitivity of both
androgen-dependent PCa (LNCaP) and CRPC (22Rv1) cells to
enzalutamide, and that co-targeting the AR axis and FAO
significantly inhibited PCa cell growth in vitro and in tu-
mours. Altogether, these studies highlight the potential
importance of lipid metabolism in CRPC. However, further
research is required to understand the interactions of AR
with lipid metabolism in driving treatment resistance and
CRPC progression, particularly in more complex tumour
environments containing multiple cell types.
One potential mechanism for the re-activation of lipid
metabolic genes is the emergence of constitutively active
AR splice variants (AR-Vs), such as AR-V7. AR-V7 lacks the C-
terminal ligand-binding domain of the full-length AR and
functions as a constitutively active, ligand-independent
transcription factor that drives the growth of metastatic
CRPC (mCRPC) cells in vitro and in vivo [127]. In support of
this, AR-V7 was shown to be increased in patients resistant
to the anti-androgen enzalutamide and abiraterone [128]. A
recent study reported that pharmacological inhibition of
FASN activity (IPI-9119) in CRPC not only suppressed fatty
acid synthesis, but also inhibited full-length AR and AR-V7
expression in androgen-dependent and androgen-
independent PCa cells [127]. Given that AR-V7 has the po-
tential to re-activate lipid biosynthesis and is associated
with treatment resistance, this suggests that AR-V7-
mediated reactivation of lipid biosynthesis (Fig. 1) may
drive disease recurrence and that targeting lipid meta-
bolism pathways in combination with ADT and AR-directed
therapies may be an effective therapeutic approach in
CRPC (particularly for patients with high AR-V expression)
or delay disease relapse.
Intriguingly, an AR blockade “bypass” mechanism was
recently proposed as a prevalent mechanism of resistance.
Upregulation of the GR was a common feature of drug-
resistant tumours as evidenced from two preclinical models
(LNCaP & VCaP) and was supported by correlative data
showing increased GR expression in patients with enzaluta-
mide resistance [129]. Importantly, comparative AR and GR
transcriptome and ChIP-Seq studies have reported that a
large majority of genes robustly regulated by GR are also
regulated by AR [129,130]. Furthermore, a recent study
revealed metabolic regulation of GR activation to stimulate
enzalutamide resistance in PCa [131], which in turn, suggests
a role for perturbed metabolic regulation in promoting
tumour progression through activation of alternative steroid
receptors. Finally, studies in non-prostatic tissues have re-
ported that the GR directly activates several genes in lipid
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findings, it is plausible that the upregulation of GR permits
the re-expression of AR-responsive genes, including genes
involved in lipid metabolism, to promote PCa progression or
CRPC.
Likewise, SREBP1-mediated activation of lipid
biosynthesis pathways is critical to survival and facilitates
progression to androgen-independence or CRPC [50,118].
Previous study showed that overexpression of SREBP1 is
sufficient to increase tumorigenicity and invasion of PCa
in vitro and its activation promoted CRPC progression
in vivo [116]. Given the reciprocal relationship between the
AR and SREBP1, SREBP1 may provide a further level of
complexity through its interactions with upstream effectors
or oncogenic signalling pathways in conjunction with AR
signaling to enable an SREBP1-dependent lipogenic program
to drive CRPC [50,116,133]. Having said all the above,
although these studies have enhanced our understanding of
how several distinct mechanisms of AR resistance may drive
PCa progression to CRPC, the opportunity now is to deter-
mine whether a coordinated signaling network exists be-
tween these previously unlinked mechanisms of AR
resistance (i.e. AR-V7, SREBP1 and GR).5. Conclusion and new opportunities
The landscape of PCa progression is intimately linked to
androgen signaling and alterations in lipid metabolism.
Androgens regulate a large repertoire of genes involved in
lipid uptake, biosynthesis, remodeling and degradation to
drive prostate cell transformation and tumor development.
Accordingly, numerous groups have exploited this facet of
metabolic reprogramming in PCa as a therapeutic vulnera-
bility by co-targeting lipid metabolism pathways with ADT
or anti-androgens (i.e. enzalutamide). In linking these ob-
servations, it is crucial that we understand the AR-driven
metabolic changes (including, but not limited to, other
lipid metabolism processes such as fatty acid elongation
and desaturation) that occur during the malignant trans-
formation of prostate epithelial cells in order to target the
key processes hijacked by tumor cells to survive. Likewise,
it is important to recognise that PCa is a highly heteroge-
nous and multifocal disease and that major discrepancies
exist between patient tissues and cell line models (partic-
ularly for metabolism) which may have significant impact
on translational applications. Cancer metabolic reprog-
ramming is profoundly impacted by spatial heterogeneity, a
fundamental feature of the tumour microenvironment
[134]. While the vast majority of research has been un-
dertaken in the epithelial cells of the normal and malignant
prostate, recent insights into the importance of metabolic
reprogramming in the TME underscore the need to broaden
our focus to different cell types in the prostate such as the
stromal fibroblasts and infiltrating immune cells. These
supporting players in the microenvironment can be co-
opted or modified by cancer cells to enhance the prolifer-
ation and invasion of the tumor, and provide exciting new
targeting strategies to improve clinical outcomes for pa-
tients with PCa. For this reason, there is an increasing need
to integrate information on lipid metabolism with spatial
information on gene expression and lipid abundance.Recent technologies such as spatial transcriptomics have
enabled transcriptomic profiling of hundreds of locations
within tissue sections with high spatial resolution to dissect
spatial metabolic heterogeneity in the tumour microenvi-
ronment and uncover novel tumour specific metabolic
vulnerabilities [135]. However, this still poses a challenge
due to the complex metabolic landscape of cancer. Mass
spectrometry imaging (MSI), on the other hand, has the
potential to distinguish tumour regions of different grade
within the same tissue specimen, and characterize histo-
logically benign tissue adjacent to the tumour to assess
field cancerization [136e138]. Accordingly, a study
demonstrated using a high-resolution matrix-assisted laser
desorption/ionization time-of-flight MSI (MALDI MSI)
method for metabolomic/lipidomic analysis and imaging of
PCa tissues to characterize metabolic signatures associated
with different Gleason scores (GS) [138]. In addition, Morse
et al. [139], used desorption electrospray ionization
coupled to MSI (DESI-MSI) to identify metabolites with dif-
ferential abundances between regions of benign and PCa
tissues which also validated with pre-established metabolic
pathways highlighting an importance in altered lipid
metabolism in PCa. In future studies, the incorporation of
patient-derived explants or xenograft models and, more
recently, human PCa organoids offers the opportunity to
elucidate the interactions between PCa and the tumour
microenvironment in systems that more closely recapitu-
late the disease heterogeneity and complexity of the
clinical tissue microenvironment to provide a more robust
mechanistic basis by which lipid metabolism may drive PCa
disease progression and treatment resistance [99].
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